Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2015, Article ID 293896, 9 pages
Research Article

New-Onset Diabetes and Glucose Regulation Are Significant Determinants of Left Ventricular Hypertrophy in Renal Transplant Recipients

1Department of Nephrology, Baskent University Medical School, 06490 Ankara, Turkey
2Department of Internal Medicine, Baskent University Medical School, 06490 Ankara, Turkey
3Department of Transplantation Surgery, Baskent University Medical School, 06490 Ankara, Turkey

Received 1 December 2014; Revised 17 February 2015; Accepted 24 February 2015

Academic Editor: Subrata Chakrabarti

Copyright © 2015 Siren Sezer et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Background. New-onset diabetes after transplantation (NODAT) is associated with decreased graft survival and an increased risk for cardiovascular disease. The objective of this study was to evaluate the risk factors for development of NODAT and its’ relationship with arterial stiffness and left ventricular mass index (LVMI) in kidney transplant recipients. Methods. 159 kidney transplant recipients were selected from our transplantation center who underwent renal transplantation between years 2007 and 2010. Results. Among 159 patients, 57 (32.2%) patients were with NODAT who were significantly older than patients without diabetes (: 0.0001). Patients with NODAT had significantly higher pulse wave velocity (PWv) (: 0.033) and left ventricular mass index LVMI (: 0.001) compared to patients without NODAT. Further analysis was done according to LVMI as follows: LVMI > 130 g/m2 (: 57) and LVMI ≤ 130 g/m2 (: 102). We observed higher office systolic and diastolic BP, serum trygliceride, glucose, creatinine, age, and HbA1c (: 0.0001) levels in patients with LVMI > 130 g/m2. Linear regression analysis revealed that HbA1c was the major determinant of LVMI (: 0.026, : 0.361). Conclusions. HbA1c is the major determinant of LVMI, so strict control of serum glucose levels is essential for preventing cardiovascular disease in patients with NODAT.